Yahoo Web Search

Search results

1. • 

     Should Children Be Enrolled in End-of-Life Clinical Studies?

     Medscape· 3 days ago

     Is it appropriate to enroll children and adolescents in end-of-life clinical studies? Experts...

2. • 

     Symptoms of CML Getting Worse

     Healthline· 7 days ago

     Learn how symptoms of chronic myeloid leukemia (CML) may change as it progresses through chronic, accelerated, and blast phases.

3. • Enliven Therapeutics (NASDAQ:ELVN) Trading 8.2% Higher

     ETF DAILY NEWS· 5 days ago

     Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price traded up 8.2% during mid-day trading on Friday . The stock traded as high as $21.85 and last traded at $21.85. 22,673 ...

4. • 

     Is Geron Stock a Buy Following Its First New Drug Approval?

     Motley Fool via Yahoo Finance· 6 days ago

     Such a complex indication could make it relatively easy for health insurers to deny reimbursement...

5. • Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Down 34.7% in May

     ETF DAILY NEWS· 1 day ago

     Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) was the target of a significant decrease in short interest during the month of May. As of May 31st, there was short interest totalling ...

6. • 

     Riding for a cause: One Mainer's journey doing the Pan-Mass Challenge

     WCSH 6 Portland· 7 days ago

     According to the Dana-Farber Cancer Institute, its cancer hospital was ranked #4 globally—the only...

7. • Enliven Therapeutics (NASDAQ:ELVN) Upgraded to Strong-Buy by Baird R W

     ETF DAILY NEWS· 2 days ago

     Baird R W upgraded shares of Enliven Therapeutics (NASDAQ:ELVN – Free Report) to a strong-buy rating in a research note released on Tuesday, Zacks.com reports. Several other equities analysts ...

8. • Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with...

     KSAN - KLST San Angelo· 3 days ago

     Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ...

9. • CIBC Asset Management Inc Decreases Stock Position in Incyte Co. (NASDAQ:INCY)

     ETF DAILY NEWS· 5 days ago

     CIBC Asset Management Inc decreased its position in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 3.9% in the 4th quarter, Holdings Channel reports. The fund owned 26,536 shares of the ...

10. • Thomas Tray Sells 1,093 Shares of Incyte Co. (NASDAQ:INCY) Stock

      ETF DAILY NEWS· 2 days ago

      Incyte Co. (NASDAQ:INCY – Get Free Report) insider Thomas Tray sold 1,093 shares of the stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $58.91, for ...